Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Inventory (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Change in Inventory for 4 consecutive years, with $181000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Inventory rose 10.37% to $181000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $132000.0, a 37.5% increase, with the full-year FY2024 number at $28000.0, up 121.37% from a year prior.
  • Change in Inventory was $181000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $49000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $197000.0 in Q3 2022 to a low of -$60000.0 in Q4 2024.
  • A 4-year average of $19800.0 and a median of -$36000.0 in 2022 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 500.0% in 2024; the steepest drop was 850.0% in 2024.
  • Orchestra BioMed Holdings' Change in Inventory stood at -$54000.0 in 2022, then skyrocketed by 114.81% to $8000.0 in 2023, then tumbled by 850.0% to -$60000.0 in 2024, then skyrocketed by 401.67% to $181000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Change in Inventory are $181000.0 (Q3 2025), $49000.0 (Q2 2025), and -$38000.0 (Q1 2025).